Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1975 5
1976 4
1977 14
1978 9
1979 5
1980 14
1981 9
1982 13
1983 11
1984 15
1985 9
1986 10
1987 8
1988 16
1989 16
1990 11
1991 16
1992 19
1993 23
1994 28
1995 29
1996 36
1997 45
1998 34
1999 39
2000 56
2001 27
2002 37
2003 50
2004 57
2005 69
2006 67
2007 68
2008 57
2009 54
2010 53
2011 58
2012 57
2013 41
2014 32
2015 28
2016 39
2017 28
2018 21
2019 22
2020 16
2021 17
2022 16
2023 17
2024 6
2025 17
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,348 results

Results by year

Filters applied: . Clear all
Page 1
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Glauser TA, et al. N Engl J Med. 2010 Mar 4;362(9):790-9. doi: 10.1056/NEJMoa0902014. N Engl J Med. 2010. PMID: 20200383 Free PMC article. Clinical Trial.
RESULTS: The 453 children who were randomly assigned to treatment with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their demographic characteristics. After 16 weeks of therapy, the freedom-from-failure rates for ethosux …
RESULTS: The 453 children who were randomly assigned to treatment with ethosuximide (156), lamotrigine (149), or valproic acid …
Phenobarbital--valporic acid interaction.
Patel IH, Levy RH, Cutler RE. Patel IH, et al. Clin Pharmacol Ther. 1980 Apr;27(4):515-21. doi: 10.1038/clpt.1980.72. Clin Pharmacol Ther. 1980. PMID: 6766833 Clinical Trial.
In the other, subjects received 250 mg valproic acid orally twice daily for 14 consecutive days and a 60-mg dose of phenobarbital orally on day 4. ...The findings indicate that valproic acid inhibits phenobarbital metabolism....
In the other, subjects received 250 mg valproic acid orally twice daily for 14 consecutive days and a 60-mg dose of phenobarbi …
Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I.
Krosschell KJ, Kissel JT, Townsend EL, Simeone SD, Zhang RZ, Reyna SP, Crawford TO, Schroth MK, Acsadi G, Kishnani PS, Von Kleist-Retzow JC, Hero B, D'Anjou G, Smith EC, Elsheikh B, Simard LR, Prior TW, Scott CB, Lasalle B, Sakonju A, Wirth B, Swoboda KJ; Project Cure SMA Investigator's Network. Krosschell KJ, et al. Muscle Nerve. 2018 Feb;57(2):193-199. doi: 10.1002/mus.25776. Epub 2017 Sep 18. Muscle Nerve. 2018. PMID: 28833236 Clinical Trial.
INTRODUCTION: The aim of this study was to determine the safety and therapeutic potential of L-carnitine and valproic acid (VPA) in infants with spinal muscular atrophy (SMA). METHODS: Our investigation was an open-label phase 2 multicenter trial of L-carnitine and …
INTRODUCTION: The aim of this study was to determine the safety and therapeutic potential of L-carnitine and valproic acid (VP …
Drug therapy: Valproic acid.
Koch-Weser J, Browne TR. Koch-Weser J, et al. N Engl J Med. 1980 Mar 20;302(12):661-6. doi: 10.1056/NEJM198003203021204. N Engl J Med. 1980. PMID: 6766529 Review. No abstract available.
Neuroprotective, cognitive, and immunomodulatory effects of Valproic acid combined with dextromethorphan in bipolar disorder.
Huang CC, Tzeng NS, Chang YH, Hong JS, Lu RB. Huang CC, et al. J Psychiatr Res. 2026 Jun;197:118-124. doi: 10.1016/j.jpsychires.2026.02.038. Epub 2026 Feb 25. J Psychiatr Res. 2026. PMID: 41774971 Clinical Trial.
Valproic acid (VPA) is recognized for its neurotrophic properties and is widely used in psychiatric and peripheral disorders, while dextromethorphan (DM) has demonstrated anti-inflammatory and neuroprotective effects. ...
Valproic acid (VPA) is recognized for its neurotrophic properties and is widely used in psychiatric and peripheral disorders, …
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG. Bug G, et al. Cancer. 2005 Dec 15;104(12):2717-25. doi: 10.1002/cncr.21589. Cancer. 2005. PMID: 16294345 Free article. Clinical Trial.
BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute myeloid leukemia (AML) blasts, an effect enhanced by all-trans retinoic acid (ATRA). ...
BACKGROUND: Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induced in vitro differentiation of primary acute mye …
A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma.
Liu YC, Su CW, Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH. Liu YC, et al. Asia Pac J Clin Oncol. 2022 Feb;18(1):19-27. doi: 10.1111/ajco.13443. Epub 2020 Sep 22. Asia Pac J Clin Oncol. 2022. PMID: 32964588 Clinical Trial.
New chemoregimens with cytotoxicity modulators were explored to improve efficacy. Chemotherapy modulated with valproic acid (VA) as a deacetylation inhibitor of histone and DNA damage response proteins, and hydralazine (HZ) as a DNA hypomethylating agent, hypothetic …
New chemoregimens with cytotoxicity modulators were explored to improve efficacy. Chemotherapy modulated with valproic acid (V …
Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Georgoff PE, et al. Clin Pharmacokinet. 2018 Feb;57(2):209-219. doi: 10.1007/s40262-017-0553-1. Clin Pharmacokinet. 2018. PMID: 28497259 Free PMC article. Clinical Trial.
BACKGROUND: Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseases, and traumatic injuries. In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mort …
BACKGROUND: Valproic acid, a histone deacetylase inhibitor, has beneficial effects in the setting of cancer, neurologic diseas …
Valproic acid in epilepsy: clinical and pharmacological effects.
Mattson RH, Cramer JA, Williamson PD, Novelly RA. Mattson RH, et al. Ann Neurol. 1978 Jan;3(1):20-5. doi: 10.1002/ana.410030105. Ann Neurol. 1978. PMID: 350128 Clinical Trial.
The antiepileptic drug valproic acid was studied in an open clinical trial as adjunct medication for 23 patients with uncontrolled seizures of a generalized or partial type. ...This observation was interpreted as a drug interaction: valproic acid compe …
The antiepileptic drug valproic acid was studied in an open clinical trial as adjunct medication for 23 patients with uncontro …
Therapeutic drug monitoring of valproic acid.
Shaikh AS, Liu H, Li Y, Cao L, Guo R. Shaikh AS, et al. Pak J Pharm Sci. 2018 Jul;31(4(Special)):1773-1776. Pak J Pharm Sci. 2018. PMID: 30203778 Clinical Trial.
The unpredictable and unfavorable connection of dose and plasma concentration of valproic acid supports the necessity to regularly measure its plasma concentration. The present study is drug monitoring of valproic acid and comparative evaluation of the …
The unpredictable and unfavorable connection of dose and plasma concentration of valproic acid supports the necessity to regul …
1,348 results